Modulation of regulatory T cells by human IL-18
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-038/19
A61K-038/20
출원번호
US-0250425
(2011-09-30)
등록번호
US-8679471
(2014-03-25)
발명자
/ 주소
Carroll, Richard G.
Shan, Xiaochuan
Danet-Desnoyers, Gwenn-ael
June, Carl H.
출원인 / 주소
The Trustees of the Univesity of Pennsylvania
대리인 / 주소
Howson & Howson, LLP
인용정보
피인용 횟수 :
0인용 특허 :
2
초록
The present invention relates to compositions and methods for modulating the presence and/or activity of regulatory T cells in a subject.
대표청구항▼
1. A method of treatment comprising: administering a therapeutically-effective amount of interleukin 18 (IL-18) to a subject in need thereof,detecting the level of CD4+CD25+FoxP3+ Tregs in the subject, wherein the level of CD4+CD25+FoxP3+ Tregs is reduced as compared to the level of Tregs in the sub
1. A method of treatment comprising: administering a therapeutically-effective amount of interleukin 18 (IL-18) to a subject in need thereof,detecting the level of CD4+CD25+FoxP3+ Tregs in the subject, wherein the level of CD4+CD25+FoxP3+ Tregs is reduced as compared to the level of Tregs in the subject prior to treatment; andadministering a second therapeutic. 2. The method of claim 1, wherein said level of Tregs is reduced to a zero number of detectable cells. 3. The method of claim 1, wherein said IL-18 is human IL-18. 4. The method of claim 1, wherein said subject is a human subject. 5. The method of claim 4, wherein said human subject is afflicted with at least one disorder selected from cancer, a retroviral infection or a parasitic infection. 6. The method of claim 5, wherein said cancer is lung cancer, gastrointestinal cancer, genitourinary tract cancer, liver cancer, bone cancer, nervous system cancer, gynecological cancer, breast cancer, hematologic cancer, skin cancer, or adrenal gland cancers. 7. The method of claim 6, wherein the cancer is lung cancer. 8. The method according to claim 1, wherein said subject is afflicted with cancer. 9. A method according to claim 8, wherein the Treg cells are systemic or intratumoral. 10. The method of claim 1, wherein said second therapeutic component is an antibody, an antibody-toxin conjugate, a toxin, a chemotherapeutic molecule, a DNA vaccine, an antisense molecule, an siRNA molecule, a stem cell, a tumor-specific T cell, or an antigen-presenting cell. 11. The method of claim 1, wherein said IL-18 is administered as part of an allogeneic tissue transplant. 12. The method of claim 11, wherein said tissue transplant is selected from peripheral blood mononuclear cell (PBMC) transplant or bone marrow transplant (BMT). 13. The method of claim 1, wherein said IL-18 is conjugated to polyethylene glycol (PEG). 14. The method of claim 1, wherein the IL-18 is administered prior to administration of a second therapeutic. 15. The method of claim 1, wherein the IL-18 is administered after vaccination with tumor-antigen pulsed dendritic cells. 16. The method of claim 1, wherein the IL-18 is administered intratumorally. 17. A method for treating a subject afflicted with lung adenocarcinoma, said method comprising administering a therapeutically-effective amount of IL-18 to said subject, anddetecting the level of CD4+CD25+FoxP3+ Tregs in the subject, wherein the number of Treg cells is decreased in said subject as compared to the level of Tregs in the subject prior to treatment. 18. The method of claim 17, wherein the IL-18 is administered prior to administration of a second therapeutic.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (2)
Terman, David S., Intrathecal and intratumoral superantigens to treat malignant disease.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.